Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 366

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 366
---
, which remains in development. Nonetheless, we believe that the B2B2C model will facilitate more efficient scaling with lower operational costs, broader geographic reach, and deeper market penetration through trusted local partners. 181 Our Operating Segments We operate across two segments within our corporate structure, dedicated to providing precise and secure biological data to empower individuals to make informed health choices. Our business units operate at the forefront of scientific development, genetic testing and will be integrated with AI -driventechnology, designed to address the entire spectrum of healthcare needs, spanning prevention diagnosis and prognosis, integrating a wide range of clinical, biological, and lifestyle data. The services within these segments have been developed based on our experience in Latin America, allowing us to adapt our tests and results based on local language and specific needs. With a focus on precision, privacy, and accessibility, OmnigenicsAI is committed to empowering individuals and healthcare providers with the tools necessary for proactive health management through the following categories with its current brands: • Rewell: personalized wellness and preventative health solutions that integrate genetic, microbiome and lifestyle data, with nutrigenetic guidance tailored to each user. Through our digital platform, users access DNA and gut microbiome testing, paired with personalized health recommendations designed to empower individuals in making informed health decisions, particularly for chronic disease prevention and gut health. Initially distributed as a direct -to-consumerproduct, in 2025, we expect to transition the distribution of Rewell to a business -to-business-to-consumerdistribution model. Rewell’s services include consultations with certified nutrigenetic specialists, which we plan to scale through the use of AI Agents, which are designed to support users in adopting lifestyle changes based on genetic and microbiome insights.; and •Heritas Diagnostics: a suite of clinical genetic testing services focused on reproductive health, oncology, rare diseases, and clinical gut health. Our tests integrate genetic and clinical data to provide precise and actionable insights that support accurate diagnoses, effective monitoring and informed treatment decisions. We ensure that our comprehensive clinical reports deliver the necessary insights needed by both patients and physicians to interpret results and make informed treatment decisions. To enhance accessibility and support, we plan to incorporate AI Agents, expected to have its first commercial use as early as 2026, that will assist patients in interpreting their results and providing personalized treatment recommendations, complementing physician guidance. Rewell: Wellness and Prevention We believe that Rewell will be at the forefront of wellness and prevention, enabling consumers to obtain personalized genetics and gut microbiome information, with